Cathie Wood to Unleash "Ark on Steroids" to the World

ARK Invest looks to test an extremely risky new strategy that could pay off massively for Cathie Wood if her predictions come to fruition
Nov. 29, 2021
Unlock Free Stock Insights + 50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

Founder and CEO of ARK Invest Cathie Wood unveiled a radical new strategy for the company last week. Wood is testing a new fund that will actively bet against major stocks that are being disrupted in the market. 

This bold plan has the potential to be amazingly lucrative for investors but comes with a huge associated risk. Let's examine the plan a little more closely.

What is "Ark on Steroids"?

Described by Wood as "Ark on steroids," the new fund is currently being tested internally by the company. It follows on from Ark's current offerings, a series of innovation ETFs, that profited billions over the course of the COVID-19 pandemic.

Wood sees institutional benchmarks as ripe for profit, particularly in a time of unprecedented industry disruption. The ARK CEO explained that "those companies have done very well historically but are going to be disintermediated and disrupted by the massive amount of innovation that's taking place."

The new fund will essentially look to short these large stocks and aim to profit off their failure to continue to grow. Short selling is of course quite a risky strategy and can lead to losses larger than if the fund had just invested in promising stock instead. However Cathie Wood appears adamant that her strategy will be fruitful, and this ETF serves as a reaffirmation of ARK's belief that innovation is key to growth.

ARK's entire strategy revolves around innovation-based, long-term growth. As such, volatility is to be expected. Its flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK), is down roughly 15% year-to-date (YTD) for example. However Wood is confident that her company's innovation picks will massively outscore the market, adding that "In five years, the world will look nothing like it does today, and we're invested in all the disruptors, the winners, that are going to disrupt the traditional world order."

So should I invest in ARK's new ETF?

The easy answer is that you can't. Not right now at least. Wood failed to give any indication as to when the fund will be accessible to the public. Right now, it continues to be solely tested within the company itself.

When, or if, it does become open to public investors, the real question you'll need to answer is just how much risk you're able to tolerate. ARK's funds are extremely volatile, and demand investment that is earmarked for the long-term. You'll have to be happy investing that money for five or ten years at the minimum before you're likely to see the results you're hoping for.

If you truly believe in the changing of the guard when it comes to global industry, and that disruption is going to continue to occur at an accelerated rate, then perhaps this ETF will be for you. If you'd rather take a more cautious approach to long-term investing, maybe we here at MyWallSt can help.

Are you looking for that right company to kickstart your portfolio? Look no further than MyWallSt, where our shortlist of market-beating stocks will take you to the next level. Don't believe us? Why not get free access today?


Unlock Free Stock Insights +50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.


Services

Content

Social

Company

Support

Resources


This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.